DTP Communications
- Resource for Providers
- Notification of Initiative Launch
- Considerations for the Prescriber
Cabotegravir and Rilpivirine Extended-Release Injectable Suspensions (Cabenuva(R))
- Notice to Prescribers
- Formulary Addition: Dolutegravir-lamivudine (Dovato®)
- Resumption of routine HIV plasma viral load testing
- Updates to BC-CfE Guidance Documents
- Notice to Prescribers
- BC-CfE Lab Notice to Prescribers